WO2016005793A1 - Procédé cosmétique. - Google Patents

Procédé cosmétique. Download PDF

Info

Publication number
WO2016005793A1
WO2016005793A1 PCT/IB2014/062973 IB2014062973W WO2016005793A1 WO 2016005793 A1 WO2016005793 A1 WO 2016005793A1 IB 2014062973 W IB2014062973 W IB 2014062973W WO 2016005793 A1 WO2016005793 A1 WO 2016005793A1
Authority
WO
WIPO (PCT)
Prior art keywords
individual
vitamin
acid
defect
skin
Prior art date
Application number
PCT/IB2014/062973
Other languages
English (en)
Inventor
Maurizio Esposito
Original Assignee
Suisse Life Science S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suisse Life Science S.A. filed Critical Suisse Life Science S.A.
Priority to PCT/IB2014/062973 priority Critical patent/WO2016005793A1/fr
Priority to EP14761409.3A priority patent/EP3167074A1/fr
Publication of WO2016005793A1 publication Critical patent/WO2016005793A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/148—Screening for cosmetic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • the present invention relates to a cosmetic method for prevention and/or cosmetic improvement of aesthetic defects.
  • hard-to-treat defects are known, such as excess localized fat, tendency to overweight, achievement/maintenance of the ideal weight, cellulite defects, skin aging, skin sagging, hair aging and alopecia.
  • One object of the present invention is to provide a method for cosmetic prevention or treatment of defects affecting beauty, even when they are hardly removable, that provides long-lasting natural looking results.
  • One purpose of the present invention is to provide a method for prevention or cosmetic improvement of defects, that is easy to use and reliable.
  • Another object of the present invention is to provide a method for prevention or cosmetic improvement of defects that can be easily used by an individual who needs it.
  • a method of achieving cosmetic improvement and/or prevention of a defect in an individual which comprises the steps of:
  • SNP single-nucleotide polymorphism
  • step b) assigning a score to the result of each determination of step a);
  • step c) obtaining history information from the individual, concerning his/her current and past lifestyle, food habits and health, by submitting a set of standardized questions; d) assigning a score to the result of each determination of step c);
  • step e) assigning a total score to the individual, as determined from from the results of steps b) and d), using a genetic/lifestyle assessment algorithm, which relates the results of the genetic test to the effects of the lifestyle of the individual, and weights them; f) administering one or more substances for cosmetic improvement and/or prevention of the defect to the individual, with the type and amount of substance being determined according to the result of step e).
  • defects is intended to designate alterations of the normal state of the skin or anyway the exterior appearance of an individual, irrespective of his/her physiological condition and of any disease associated with such alterations.
  • Non-limiting examples of such defects are localized fat, tendency to overweight, androgenetic alopecia, cellulite, skin aging, skin sagging.
  • Active substance names as used herein are INCI (International Nomenclature of Cosmetic Ingredients) names, e.g. according to the Cosmetic Directive 76/768/EEC, the European Commission Decision 96/335/EC, the Regulation (EC) No. 1223/2009 of the European Parliament and the Council of 30 November 2009 on cosmetic products and later updates.
  • INCI International Nomenclature of Cosmetic Ingredients
  • the present invention relates to a method of achieving cosmetic improvement and/or prevention of a defect in an individual, comprising the steps of: a) performing a genetic test on a biological sample taken from the individual to find any possible single-nucleotide polymorphism (S P);
  • step b) assigning a score to the result of each determination of step a);
  • step c) obtaining history information from the individual, concerning his/her current and past lifestyle, food habits and health, by submitting a set of standardized questions; d) assigning a score to the result of each determination of step c);
  • step e) assigning a total score to the individual, as determined from from the results of steps b) and d), using a genetic/lifestyle assessment algorithm, which relates the results of the genetic test to the effects of the lifestyle of the individual, and weights them; f) administering one or more substances for cosmetic improvement and/or prevention of the defect to the individual, with the type and amount of substance being determined according to the result of step e).
  • the present invention provides a highly customized predictive method, comprising predictive genetic analysis for cosmetic applications, which may be combined with nutritional/cosmetic treatments for an individualized treatment plan.
  • the purpose of the method is to allow predictive identification of defects, such as by a novel application of applied genetics or genomics, in combination with nutritional/cosmetic treatments, with a treatment and prevention plan tailored for each individual.
  • S P Single Nucleotide Polymorphism
  • Targeted reading of particular SNPs and their correlation, by the use of targeted substances allows determination of well-defined paths of customized medicine, possibly with a biomedical approach.
  • the method of the present invention includes:
  • This first step leads to the preparation of a report which provides the keys to address the defects, as determined by the interpretation of the genetic results according to the method of the invention.
  • Sequencing of the DNA sample allows quick identification of risk areas, which may affect visible and non-visible effects in the biological processes determined by the individual genetics.
  • Active substances are selected among naturally occurring substances, or substances that have already been tested in the medical/cosmetic field and have been proven to be safe for the patient, when used as known by the skilled person.
  • Each DNA analysis is provided with a total score, given with reference to the average score of the European/Caucasian population; the area that dominates the biological processes to be targeted to counteract the defects and the main areas are shown with customized scores, related to the population.
  • the genetic result is valid throughout the lifespan of the individual.
  • a set of rules and criteria is defined for quantification of the "level of well-being" of the individual with respect to the aesthetic defect under examination and the biological processes that cause or affect it.
  • the criteria are based on evidence and international literature, as well as non nutritional and lifestyle considerations.
  • the algorithm is also applied to the available genetic results and historical information about the individual.
  • the "level of well-being" of a person is determined by combining a number of genetic and non-genetic indicators (scores), which represent:
  • each possible genetic result is assigned one of 3 possible scores (step b)):
  • each SNP is assigned a weight number expressing:
  • a score is also determined from the history-taking questions (steps c) and d)).
  • the final score for each area is obtained as an average of the genetic score and the history score.
  • the genetic component is assigned a higher score (60/70%).
  • the scores of each area are averaged, according to their weights.
  • +1 designates a favorable overall predisposition (total score).
  • the total score of the panel is reprocessed on a scale from 0 to 100. This result may be considered as a percent "level of well-being" with respect to the defect under examination and the particular individual.
  • the new score is determined as follows:
  • the 0-100 score is the reference index of the method of the invention, which indicates the treatment level suggested by a proprietary algorithm, based on genetic guidance and correction of the interference of individual habits and on history self-assessment. According to the relevance of the area of the panel, the method of the invention indicates the area index as a reference for treatment or as a total index of the genetic panel.
  • the scale of the index ranges from 100 to 0.
  • the algorithm of the inventive method includes a selection of suggested products among potentially available cosmetic products and dietary supplements.
  • Selection is based on SNP scores, accoding to the following logic:
  • Table 1 shows an exemplary, non-limiting possibility of selection of suggested products.
  • the present invention affords customization of the therapy approach to each patient, based on his/her genetic predisposition to the particular defect to be addressed, using the biomedical approach of combination therapy.
  • the present invention provides an advanced form of customized medicine, which also provides pro-active prevention to also counteract, with time, non-genetic, environmental or lifestyle risk factors, using dietary supplements and phytocomplexes.
  • the method of the invention also comprises diet and lifestyle correction.
  • the assessment of step c) may be carried out before, at the same time as or after steps a) and b).
  • the defect is at least one of localized fat, tendency to overweight, androgenetic alopecia, cellulite, skin aging and skin sagging.
  • the method of the invention was surprisingly found to afford cosmetic improvement and/or prevention of an aesthetic defect in an individual through an unique relationship of the presence of a SNP or a combination of SNPs to the administration of one or more biologically active substances.
  • Such administration may be an oral or topical administration, using methods and appropriate formulations as known by the skilled person, such as suspensions, tablets, capsules, creams, ointments, lotions, spray, etc.
  • the administration is an oral administration.
  • the substance administered in step f) is at least one substance selected from Bromelin 2500 GDU; Opuntia ficus indica extract (Nopal®); Triterpenes (Centella asiatica extract); Vitexin; Ruscogenin; Polyphenols; Tannins; Catechins EGCG - ECG; Chrome; L-Isoleucine; L-Taurine; L-Carnitine; L- Lysine; L-Valine; L-Arginine; L-Selenium methionine; Hydroxycitric acid; Synephrine; Vitamin B6; Ellagic acid; Biotin (vitamin H); Alpha lipoic acid; Superoxide dismutase 560 UI; Niacin (vitamin B3); Vitamin C; Vitamin D; Fatty acids (Serenoa repens); Iron; Copper; Chrome; Zinc; Potassium; Lignans; Silica; Melatonin; Fucoxanthine; L-Carnitine
  • the parameters under examination are those related to oxygenation, vasodilation, alteration of mucrocirculation, vascularization, homonal factors and presence of skin inflammations or alterations, which impart the typical orange peel look thereto.
  • the dominant area is oxygenation / vasodilation / alteration of the microcirculation / vascularization.
  • the genes under examination are:
  • HIFla it is a transcription factor whose alpha subunit is directly regulated by oxygen tension
  • HIFla assists the cell to reestablish oxygen homeostasis, associated with the homeostasis alteration, adipose tissue hypoxia slows down metabolic waste removal.
  • the resulting liquid stagnation and chronical inflammation leads to sclerosis, i.e. hardening, of fat.
  • water retention is intended to designate an accumulation of liquids in interstitial spaces (between cells), which causes abnormal swelling (edema), in certain areas of the body such as belly, thighs, buttocks and ankles. 30% of Italian women are affected by water retention, which may be caused by a salt-rich diet or by improper functioning of the venous and lymphatic systems or by hormone disequilibrium. It is associated with questions about:
  • Circulatory problems worsening of the circulatory state, with venous and lymphatic return insufficiency;
  • Smoking cigarettes finally leads to rigidity of arterial walls, with reduced oxygen delivery to the periphery and consequent tissue hypoxia and reduced lipolysis (fat breakdown); it also promotes the production of free radicals that can cause damage to small vessel walls.
  • Estrogen receptor associated with the cascade of events that lead to ovulation.
  • Estrogens may be the main hormones that initiate and worsen cellulite.
  • the hormone supply of women is richer in estrogens, which promote accumulation of excess weight on the lower part of the body, with water retention and circulatory stasis. It is associated with hormone disequilibrium. Increased levels of estrogens cause accumulation of excess weight on the lower part of the body, with water retention and circulatory stasis.
  • Cellulite mainly affects women, due to a hormonal factor (greater production of estrogens, which facilitate deposition of fat).
  • - ILIA It is a pro-inflammatory cytokine that has a major role in local and systemic inflammation.
  • the targets of these cytokines are not only the cells of the immune system, as these cytokines can adhere to endothelial cells and fibroblasts, thereby affecting replication of epithelial cells, endothelial cells and fibroblasts.
  • the latter stimulate collagen synthesis, which is important for the tightness of venous vessel walls, as it increases the resistance of blood vessel walls and reduces their permeability. This improves microcirculation and increases oxygen delivery to tissues. It is associated with an alteration of the local and systemic inflammatory response.
  • a hyperactivation of the immune system causes increased production of free radicals, which have a cell membrane disrupting function, and cause accumulation of liquids in the tissue.
  • Fat-rich diet it increases inflammatory processes
  • Smoke it increases inflammatory processes. Smoking cigarettes finally leads to rigidity of arterial walls, with reduced oxygen delivery to the periphery and consequent tissue hypoxia and reduced lipolysis (fat breakdown); it also promotes the production of free radicals that can cause damage to small vessel walls.
  • a diet with fish at least twice a week affords an adequate intake of Omega-3 which assist in counteracting inflammation.
  • Free radicals are dangerous because they have a destructive action on cells and the fats that form their membranes. It should be note that high levels of free radicals were also found in sedentary persons under psychophysical stress.
  • the aesthetic defect is cellulite and the SNP polymorphism determined in step a) is at least one of ACE, E S1, HIFla, ILIA, MTHFR and NOS3 and combinations thereof and, more preferably, in this case the substance administered in step f) is at least one substance selected from Bromelin 2500 GDU; Fucoxanthine, Opimtia ficus indica extract (Nopal®); Polyphenols, Ruscogenin, Tannins, Triterpenes (Centella asiatica extract), Vitexin and mixtures thereof.
  • the parameters under examination are those related to fat mass levels, body composition, sugar metabolism, fat distribution and lipid metabolism.
  • the dominant area (Area 1) relates to fat mass levels and body composition.
  • the genes under examination comprise:
  • - MC4R Optimal regulation of appetite and sense of fullness; normal fat mass levels; lower predisposition to type 2 diabetes and obesity. Decreased sense of fullmess and increased appetite stimulation. Increase of weight, namely of fat mass. Predisposition to obesity and hence to type 2 diabetes.
  • AREA 2 Sugar metabolism, fat distribution, include the assessment of the following genes:
  • ADRB2 It is a receptor involved in fat mobilization and maintenance of glucose levels in blood, and regulates removal of excess fat
  • - PPARG Transcription factor affecting glucose and insulin levels in blood, which is involved in adipocyte differentiation, and is associated with insulin sensitivity, metabolism and sugars. Influence of disequilibrium on insulin levels; predisposition to type 2 diabetes. Increased risk of obesity, metabolic syndrome and cardiovascular risk, the inventive method it is associated with questions about:
  • AREA 3 concerning lipid metabolism.
  • the associated genes comprise:
  • Lipoprotein lipase it hydrolyzes the triglycerides contained in the lipoproteins and has the purpose of collecting and carrying lipids, associated with an increased risk of cardiovascular diseases due to high levels of triglycerides and lower levels of HDL (good cholesterol)
  • PCSK9 it is the protein involved in the metabolism of LDL cholesterol (bad cholesterol), which is implied in familial hypercholesterolemia and induced lipid accumulation with localized adiposity. It is connected to an increased risk of coronary diseases.
  • the aesthetic defect is localized fat and the SNP polymorphism determined in step a) is at least one of ADRB2, FTO, ILIA, LPL, MC4R, MTHFR, PCSK9 and PPARG or combinations thereof and, more preferably, in this case, the substance administered to the individual in step f) is at least one of bromelain, caffeine, carnitine, Escine, isomerized linoelic acid (CLA), triethanolamine hydroiodide (TEA hydroiodide), peel of Citrus aurantium, sodium hyaluronate, theobromine, thioctic acid, tocopherol acetate and mixtures thereof.
  • the parameters under examination relate to genetic predisposition, presence of antioxidants and, based on genetic analysis only, a percent risk of developing alopecia at 30, 50 and 70 is further determined.
  • the dominant area is genetic predisposition.
  • the genes assessed in the inventive method are:
  • Androgen receptor that binds various steroid hormones and affects the development of secondary sexual characters
  • WNT10A Gene coding for signal molecules implied in cell regulation factors The strongest association signal was obtained for rs7349332 which is located in WNT10A. Studies on the expression in the human hair follicle indicate that WNT10A has a functional role in the etiology of AGA (androgenetic alopecia). These studies provide genetic evidence to support involvement of the W T signal in AGA development, which is associated with an increased predisposition to androgenetic alopecia.
  • (glutathione peroxidase) is an enzymatic antioxidant. It regulates the oxidoreductive cell equilibrium. It also counteracts the formation of free radicals also at skin level. Inefficiency of detoxification mechanisms with free radical accumulation. It is associated with alopecia aerata.
  • Alopecia aerata is a disease in which the abrupt fall of hair, or other body hairs, typically occurs in bald spots or areas (stage I- VII).
  • the aesthetic defect is androgenetic alopecia and the SNP polymorphism determined in step a) is at least one of AR, 20pl 1 , EDAR, GPX, MC4R and WNT 1 OA or combinations thereof or, more preferably, in this case, the substance administered to the individual in step f) is at least one of Bromelain, Caffeine, Carnitine, peel of Citrus aurantium, Escine, isomerized linoleic acid (CLA), Sodium hyaluronate, triethanolamine hydroiodide (TEA hydroiodide), Copper tripeptide-1 ; dextrane (e) acetyl tetrapeptide-3 (e) Trifolium pratense extact, Octapeptide-2, Serenoa serrulata extract; sh-Polypeptide-3; Sodium DNA, potassium glutathione, isomerized linoleate and mixtures thereof.
  • the substance administered to the individual in step f)
  • the parameters under examination are related to the texture, elasticity, tissue remodeling, skin type, detoxification and oxidative stress, vascularization and oxigenatin and inflammation.
  • the dominant area is texture/elasticity/tissue remodeling.
  • the following genes are assessed, without limitation:
  • - FLG It is an aggregation protein and the main component of keratohyalin granules in human epidermis. It has the purpose of holding the epidermis cells together and maintaining the horny layer hydrated, and is also a key protein for epidermal differentiation. It may be also associated with incomplete adhesion of keratinocytes with an alteration of the epidermal barrier protection function, which causes increased exposure damaging caused by external agents. It also predisposes the skin to intense dryness-related problems.
  • MMP3 The metalloproteinases are a group of enzymes implied in extracellular matrix degradation and in various tissue remodeling-related processes.
  • MMP3 or stromelisine is a proteoglycan strictly associated with the collagen mainly secreted by cells of the connective tissue and by basal keratinocytes. Its purpose is degrading extracellular matrix components such as laminin, fibronecting and type IV collagen. For this reason it is involved in tissue remodeling processes.
  • MMP3 is induced by inflammatory cytokines, and all stimulations that cause inflammation are caused by early skin aging.
  • - ELN It is the main constituent (70-90%) of elastic fibers and its strictly structural role is to impart elasticity and resistance to tissues.
  • An unfavorable variant thereof is associated with decreased skin extension, elasticity, compactness, softness, which facilitates skin aging. It is connected to decreased skin extension, elasticity, compactness and softness. Aging.
  • AREA 2 Skin type.
  • the genes assessed in the inventive method comprise:
  • - PPARG cell receptor acting on glucose and insulin levels in blood. Increase of adipose tissue. Alterations in the regulation of the lipid film with increased presence of subcutaneous fat, a typical symptom of oily skin and acne. It is associated with questions about:
  • AREA 3 Detoxification and oxidative stress.
  • the genes assessed in the method of the present invention comprise:
  • - SOD it is an antioxidant enzyme that can neutralize the superoxide, which is a dangerous free radical of oxygen. Its role is to protect cells from the oxidative stress induced by free radicals, which are among the most important photoaging factors. It is connected with free radical accumulation and oxidative stress, and consequently with photoaging.
  • - GSTT/GSTM they are part of the class of detoxifying enzymes, that can reduce the toxicity and reactiveness of dangerous compounds, through conjugation with glutathione. They are thought to be related to decreased removal of toxic substances from the body and to increased oxidative stress.
  • a further investigation area in the field of skin aging is vascularization and oxygenation.
  • the genes assessed in the inventive method comprise:
  • - NOS3 it is one of the most important molecules of the cardiovascular system, and is involved in the processes of vasodilation and regulation of blood flow. Also, it is involved in tissue repair processes after injury. A skin having an adequate nitric oxide intake is less compact and reactive and has a lower ability of defense and regeneration upon exogenous stimuli.
  • AREA 5 Inflammation
  • the genes assessed in the inventive method comprise:
  • - T F it is a pro-inflammatory cytokine, of both acute and chronic phases. Unfavorable variants may facilitate the occurrence of phlogistic phenomena and increase cardiovascular diseases. Excessive phologosis promotes cardiovascular diseases. An increased production of this cytokine is connected to a higher risk of phlogistic phenomena and skin aging. Photoaging processes are often associated with a loss of subcutaneou s fat at the face, and with the consequent occurrence of wrinkles and skin folds
  • the aesthetic defect is skin aging and the SNP polymorphism determined in step a) is at least one of ELN, FLG, GSTT/GSTM, MMP3, NOS3, SOD and TNF and more preferably, in this case, the substance administered to the individual in step f) is at least one of Acetyl decapeptide-3, Acetyl tetrapeptide-5, low and medium molecular weight hyaluronic acid, Dextrane palmytol hexapeptide-19, Dioscorrea villosa extract, Dipeptide diaminobutyrol benzylamide diacetate, Hydrolized rice protein, glycine soja protein, superoxide dismutase, Hydrolyzed verbascum thapsus flower, soybean isoflavones, Palmytol tripeptide-5, sh- Oligopeptide-1, Sodium hyaluronate crosspolymer, Superoxide dismutase,
  • the parameters under examination are related to texture and elasticity, resistance and elasticity, presence of antioxidants and hydration.
  • the dominant area is texture/elasticity.
  • the genes assessed in the inventive method in this area comprise: - COL3A1 : Collagen is the main protein of the connective tissue. Type 3 collagen is the most important constituent of extracellular matrix. It is important because it holds the cell elements together and initiates tissue and organ formation processes. It is the main fibrous element of skin, tenons, cartilages and vessels. It is also responsible for the mechanical protection of the body provided by the skin, for the skin state, for maintenance of texture quality and prevention of skin dehydration, for maintenance of elasticity and tone and finally for wrinkle minimization. It is connected to skin tone loss, with decrease of skin elasticity and increase of sagging. Skin appears more dehydrated, dry and with wrinkles and age effects
  • - EMILIN1 it helps to maintain a good quality of elastic fibers and consolidates dermal architecture by ensuring the bond between elastic fibers and collagen fibers. It is connected to alterations of elastic fibers, lower dermal compactness with sagging that may result in unaesthetic surface wrinkles, stretch marks or expression lines. It is associated with questions about:
  • AREA 2 Resistance/elasticity [additional dominant area].
  • the genes assessed in the inventive method in this area comprise:
  • Hyaluronic acid synthase is one of the basic constituents of the connective tissue in man, and imparts resistance properties and form maintenance to skin, due to its hydrating and antioxidant properties. Its concentration in tissues tends to decrease with age. It also has cicatrizing and anti-inflammatory properties. It is connected to skin resistance weakening with loss of tone and wrinkle and defect formation.
  • Skin type e.g. dry skin
  • AREA 3 Antioxidants.
  • the genes assessed in the inventive method in this area comprise:
  • Hyaluronic acid synthase it is one of the basic constituents of the connective tissue in man, and imparts resistance properties and form maintenance to skin, due to its hydrating and antioxidant properties. Its concentration in tissues tends to decrease with age. It also has cicatrizing and anti-inflammatory properties. It is connected to deficiencies of antioxidant and anti-inflammatory mechanisms, and resulting oxidative stress. Skin weakening with formation of wrinkles and defects.
  • (glutathione peroxidase) is an enzymatic antioxidant. It regulates the oxidoreductive cell equilibrium. It also counteracts the formation of free radicals also at skin level.
  • An optimal antioxidant barrier protects the skin from photoaging damages caused by UVA radiation, and can counteract free radical production and the resulting oxidative stress associated with environmental pollution, smoke, wrong diet. It is connected to inefficiencies of detoxification mechanisms with free radical accumulation. The resulting oxidative stress promotes photoaging processes, and chronic skin damages caused by the damaging action of ultraviolet radiation.
  • Menopause the lack of estrogens following the menopause causes skin atrophy and accelerated skin aging.
  • AREA 4 Hydration [additional dominant area]: The genes assessed in the inventive method in this area comprise:
  • Hyaluronic acid synthase it is one of the basic constituents of the connective tissue in man, and imparts resistance properties and form maintenance to skin, due to its hydrating and antioxidant properties. Its concentration in tissues tends to decrease with age. Therefore, as it lacks, the skin becomes weaker with formation of wrinkles and defects. It also has cicatrizing and anti-inflammatory properties. It is connected to a decrease of hydration, with loss of tone and wrinkle and defect formation.
  • the aesthetic defect is skin sagging and the SNP polymorphism detennined in step a) is at least one of COL3A1, EMILINl, GPX and HAS1 and more preferably, in this case, the substance administered to the individual in step f) is at least one of low and medium molecular weight hyaluronic acid, Ceramide-3, Glycine soybean protein, soybean isoflavones, sh-Oligopeptide-1, Sodium hyaluronate crosspolymer, Superoxide dismutase, thioctic acid.
  • the invention provides a combination therapy, with a treatment plan as described above, which modulates powerful active agents correlated to the identified biological processes, during an active biomedical therapy stage, followed by a follow-up stage.
  • a treatment plan as described above, which modulates powerful active agents correlated to the identified biological processes, during an active biomedical therapy stage, followed by a follow-up stage.
  • the nature of the defects to be corrected suggests administration of active agents and/or biomedical interventions that may be repeated with time, for achievement of results and durability thereof.
  • the present invention comprises a biologically active substances for use in treatment and/or prevention of a disorder that leads to an aesthetic defect, in which said use comprises the steps of:
  • SNP single-nucleotide polymorphism
  • step b) assigning a score to the result of each determination of step a);
  • step c) obtaining history information from the individual, concerning his/her current and past lifestyle, food habits and health, by submitting a set of standardized questions; d) assigning a score to the result of each determination of step c);
  • step e) assigning a total score to the individual, as determined from from the results of steps b) and d), using a genetic/lifestyle assessment algorithm, which relates the results of the genetic test to the effects of the lifestyle of the individual, and weights them; f) administering one or more substances for cosmetic improvement and/or prevention of the defect to the individual, with the type and amount of substance being determined according to the result of step e).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne la prévention et/ou le traitement de défauts esthétiques.
PCT/IB2014/062973 2014-07-09 2014-07-09 Procédé cosmétique. WO2016005793A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/IB2014/062973 WO2016005793A1 (fr) 2014-07-09 2014-07-09 Procédé cosmétique.
EP14761409.3A EP3167074A1 (fr) 2014-07-09 2014-07-09 Procédé cosmétique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2014/062973 WO2016005793A1 (fr) 2014-07-09 2014-07-09 Procédé cosmétique.

Publications (1)

Publication Number Publication Date
WO2016005793A1 true WO2016005793A1 (fr) 2016-01-14

Family

ID=51492988

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/062973 WO2016005793A1 (fr) 2014-07-09 2014-07-09 Procédé cosmétique.

Country Status (2)

Country Link
EP (1) EP3167074A1 (fr)
WO (1) WO2016005793A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUA20164627A1 (it) * 2016-06-23 2017-12-23 Dermagenomic S R L Metodo per l’ottenimento di una composizione cosmetica personalizzata.
US10621164B1 (en) 2018-12-28 2020-04-14 LunaPBC Community data aggregation with automated followup
WO2021070121A1 (fr) * 2019-10-11 2021-04-15 Anatara Lifesciences Limited Composition de santé gastro-intestinale
US11574712B2 (en) 2017-11-17 2023-02-07 LunaPBC Origin protected OMIC data aggregation platform
EP4012720A4 (fr) * 2019-08-09 2023-08-30 Shiseido Company, Ltd. Procédé de test génétique pour la mise en oeuvre d'un conseil de soin de la peau

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110420157A (zh) * 2019-09-18 2019-11-08 线海睿 一种活性原液及其制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050191678A1 (en) * 2004-02-12 2005-09-01 Geneob Usa Inc. Genetic predictability for acquiring a disease or condition
WO2005111239A2 (fr) * 2004-04-30 2005-11-24 Decode Genetics Ehf. Haplotypes dans le gene homologue de la proteine d'interaction de la thioredoxine humaine (arrdc3) associe a l'obesite
US20100112570A1 (en) * 2008-10-22 2010-05-06 Interleukin Genetics, Inc. Genetic Markers for Weight Management and Methods of Use Thereof
US20100249531A1 (en) * 2009-03-19 2010-09-30 Hanlon Alaina B Medical health information system
US20110172497A1 (en) * 2010-01-08 2011-07-14 Jeffrey Ruby System, Method and Computer Program for Weight, Lifestyle and/or Disease Management Integrating Nutrition, Exercise and Behaviour Management
WO2012006669A1 (fr) * 2010-07-13 2012-01-19 Fitgenes Pty Ltd Système et procédé permettant d'établir une stratégie personnelle d'intervention sur la santé
US20120258183A1 (en) * 2009-10-16 2012-10-11 Graeme John Smith Macronutrient sensitivity
US20130053270A1 (en) * 2010-02-24 2013-02-28 Bodysync, Inc. Methods for determining gene-nutrient interactions

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050191678A1 (en) * 2004-02-12 2005-09-01 Geneob Usa Inc. Genetic predictability for acquiring a disease or condition
WO2005111239A2 (fr) * 2004-04-30 2005-11-24 Decode Genetics Ehf. Haplotypes dans le gene homologue de la proteine d'interaction de la thioredoxine humaine (arrdc3) associe a l'obesite
US20100112570A1 (en) * 2008-10-22 2010-05-06 Interleukin Genetics, Inc. Genetic Markers for Weight Management and Methods of Use Thereof
US20100249531A1 (en) * 2009-03-19 2010-09-30 Hanlon Alaina B Medical health information system
US20120258183A1 (en) * 2009-10-16 2012-10-11 Graeme John Smith Macronutrient sensitivity
US20110172497A1 (en) * 2010-01-08 2011-07-14 Jeffrey Ruby System, Method and Computer Program for Weight, Lifestyle and/or Disease Management Integrating Nutrition, Exercise and Behaviour Management
US20130053270A1 (en) * 2010-02-24 2013-02-28 Bodysync, Inc. Methods for determining gene-nutrient interactions
WO2012006669A1 (fr) * 2010-07-13 2012-01-19 Fitgenes Pty Ltd Système et procédé permettant d'établir une stratégie personnelle d'intervention sur la santé

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
G EIRIKSDOTTIR ET AL: "The interaction of adiposity with the CRP gene affects CRP levels: Age, Gene/Environment Susceptibilty-Reykjavik Study", INTERNATIONAL JOURNAL OF OBESITY, vol. 33, no. 2, 1 February 2009 (2009-02-01), pages 267 - 272, XP055153120, ISSN: 0307-0565, DOI: 10.1038/ijo.2008.274 *
IRIS M HEID ET AL: "Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution", NATURE GENETICS, vol. 42, no. 11, 10 October 2010 (2010-10-10), pages 949 - 960, XP055153218, ISSN: 1061-4036, DOI: 10.1038/ng.685 *
JONSSON A ET AL: "Assessing the effect of interaction between an FTO variant (rs9939609) and physical activity on obesity in 15,925 Swedish and 2,511 Finnish adults", DIABETOLOGIA ; CLINICAL AND EXPERIMENTAL DIABETES AND METABOLISM, SPRINGER, BERLIN, DE, vol. 52, no. 7, 17 April 2009 (2009-04-17), pages 1334 - 1338, XP019698627, ISSN: 1432-0428 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUA20164627A1 (it) * 2016-06-23 2017-12-23 Dermagenomic S R L Metodo per l’ottenimento di una composizione cosmetica personalizzata.
WO2017221161A1 (fr) * 2016-06-23 2017-12-28 Dermagenomic S.R.L. Procédé d'obtention d'un traitement cosmétique personnalisé
US11574712B2 (en) 2017-11-17 2023-02-07 LunaPBC Origin protected OMIC data aggregation platform
US10621164B1 (en) 2018-12-28 2020-04-14 LunaPBC Community data aggregation with automated followup
US11074241B2 (en) 2018-12-28 2021-07-27 LunaPBC Community data aggregation with automated data completion
US11449492B2 (en) 2018-12-28 2022-09-20 LunaPBC Community data aggregation with cohort determination
US11580090B2 (en) 2018-12-28 2023-02-14 LunaPBC Community data aggregation with automated followup
EP4012720A4 (fr) * 2019-08-09 2023-08-30 Shiseido Company, Ltd. Procédé de test génétique pour la mise en oeuvre d'un conseil de soin de la peau
WO2021070121A1 (fr) * 2019-10-11 2021-04-15 Anatara Lifesciences Limited Composition de santé gastro-intestinale

Also Published As

Publication number Publication date
EP3167074A1 (fr) 2017-05-17

Similar Documents

Publication Publication Date Title
WO2016005793A1 (fr) Procédé cosmétique.
Pham et al. Anti‑wrinkle effect of fermented black ginseng on human fibroblasts
JP6215364B2 (ja) ＭＣ−１Ｒ、ＭＣ−２Ｒ、およびμオピオイド受容体調節
Jiménez-Pérez et al. Applications of Panax ginseng leaves-mediated gold nanoparticles in cosmetics relation to antioxidant, moisture retention, and whitening effect on B16BL6 cells
Hwang et al. Antiaging effects of the mixture of Panax ginseng and Crataegus pinnatifida in human dermal fibroblasts and healthy human skin
Mohiuddin Skin aging & modern age anti-aging strategies
CN101878019B (zh) 含有具有基序gx1x2g、px1x2p或者px1x2k的四肽的个人护理和化妆品组合物
US8877264B2 (en) Composition of skin external application containing ginseng berry extracts
Li et al. Ginsenosides repair UVB-induced skin barrier damage in BALB/c hairless mice and HaCaT keratinocytes
Hong et al. Effects of porcine placenta extract ingestion on ultraviolet B-induced skin damage in hairless mice
CN116143873A (zh) 活性肽及其用于制备抗皮肤老化的药物或者化妆品中的应用
Takara et al. Oryza Ceramide®, a rice-derived extract consisting of glucosylceramides and β-sitosterol glucoside, improves facial skin dehydration in Japanese subjects
KR20120029346A (ko) 사과 추출물 및 콜라겐 트리펩티드 함유 미용 음료
RU2657824C1 (ru) Способ биокоррекции преждевременного старения организма и кожи
Hwang et al. Skin wound healing effects of (+)-syringaresinol from ginseng berry
EP2229165A1 (fr) Propriétés anti-glycation de l'acide asiatique et de l'acide madécassique
Wandrey et al. Evaluation of the collagen-boosting effects of a Moldavian dragonhead extract
Lee et al. Anti-aging Effect of Mixed Extract from Medicinal Herbs
JP2016079154A (ja) 皮膚化粧料、頭髪化粧料および飲食品
KR101081424B1 (ko) 생약재 추출물을 함유하는 피부 외용제 조성물
Bharati et al. A case study on the management of psoriasis (kitibha) by ayurvedic intervention
Draelos et al. A Multi-center Trial Evaluating a Serum Comprised of Plant-based Adaptogens Targeting Skin Quality
WO2024217163A1 (fr) Composition contenant de l'extrait de tricholoma matsutake ayant un effet anti-âge, et son utilisation
EP3568131A1 (fr) Composition comprenant du 7-hydroxymatairésinol destinée à être utilisée dans le traitement et dans la prévention de maladies trichologiques d'origine inflammatoire et/ou hormonale
Leonidovich et al. Linear skin atrophy: Current information and modern approaches to the external therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14761409

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2014761409

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014761409

Country of ref document: EP